Cited by 124Advanced Drug Delivery SystemsInhalation and Respiratory Drug DeliveryAdvancements in Transdermal Drug Delivery

Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion

Abdou, Ebtsam M., Kandil, Soha M., Miniawy, Hala M.F. El·2017·International Journal of Pharmaceutics

Abstract

Zolmitriptan (ZT) is a well-tolerated drug in migraine treatment suffering from low bioavailability due to low amount of the drug that reaches the brain after oral and nasal delivery. Development of new nasal mucoadhesive nanoemulsion formulation for zolmitriptan may success in delivering the drug directly from the nose to the brain to achieve rapid onset of action and high drug concentration in the brain which is required for treatment of acute migraine. ZT mucoadhesive nanoemulsion were prepared and characterized for drug content, zeta potential, particle size, morphology, residence time and permeation through the nasal mucosa. The selected formula was tested in-vivo in mice for its pharmacokinetics in comparison with intravenous and nasal solution of zolmitriptan. Results showed that addition of chitosan as mucoadhesive agent in 0.3% concentration to the nanoemulsion enhanced its residence time and zetapotential with no significant effect on the globule size. All tested formulations showed higher permeability coefficients than the zolmitriptan solution through the nasal mucosa. In-vivo studies showed that the mucoadhesive nanoemulsion formulation of zolmitriptan has higher AUC 0-8 and shorter T max in the brain than the intravenous or the nasal solution. This was related to the small globule size and higher permeability of the formulation.

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2017.07.030

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Important differences exist between classical macroemulsions, nanoemulsions and microemulsions in droplet size range and stability characteristics.

    “Important differences can be found between classical macroemulsions (classical emulsions), NEs and microemulsions in droplet size range and stability characteristics [32,47].”

    From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [47]

  • In Sprague-Dawley rats, mucoadhesive chitosan-containing zolmitriptan nanoemulsion presents higher AUC and shorter Tmax in the brain than intravenous or nasal solutions.

    “In vivo studies carried out on Sprague–Dawley rats showed that the mucoadhesive (chitosan containing) NE presents higher AUC and shorter Tmax in the brain than intravenous or the nasal solutions.”

    From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [47]

  • Addition of chitosan as a mucoadhesive agent at 0.3% to zolmitriptan nanoemulsions enhanced residence time and zeta potential with no relevant effect on globule size.

    “The addition to the NE of chitosan as a mucoadhesive agent in 0.3% enhanced the residence time and zeta potential of the formulation with no relevant effect on the globule size.”

    From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [47]

Cites

Flagged first, then by citations

7 of the 74 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Abdou, E. M., Kandil, S. M., & Miniawy, H. M. F. E.
Affiliations
  • National Organization for Drug Control and Research (EG)
  • Modern University for Information and Technology (EG)
  • Cairo University (EG)
Corresponding author
Abdou, Ebtsam M.
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2017-08
Volume
529
Issue
1-2
Pages
667-677
ISSN
0378-5173 (ISSN-L)
OpenAlex
W2735486104
Cited by
124
References
74
Citations by year
2026: 8 · 2025: 15 · 2024: 17 · 2023: 12 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 18 · 2018: 4
FWCI
5.51
Type
journal article
Language
en
Open access
closed
Locations
  • International Journal of Pharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
zolmitriptan, migraine, intranasal drug delivery, chitosan, nasal mucosa permeation, brain targeting, pharmacokinetics, residence time, globule size, zeta potential, acute migraine treatment
MeSH terms
Administration, Intranasal, Animals, Brain, Chemistry, Pharmaceutical, Migraine Disorders, Nasal Mucosa, Tryptamines, Oxazolidinones, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review